Loading...
•
Jul 31, 2022
Cooper Q3 2022 Earnings Report
Reported record revenues with CooperVision and CooperSurgical's fertility business showing strong organic revenue growth.
Key Takeaways
CooperCompanies announced its fiscal third quarter results with revenue increasing by 10% year-over-year to $843.4 million. CooperVision's revenue increased by 2% to $566.3 million, while CooperSurgical's revenue increased by 35% to $277.1 million. GAAP diluted earnings per share were $1.98, and non-GAAP diluted earnings per share were $3.19.
Revenue increased 10% year-over-year to $843.4 million.
CooperVision (CVI) revenue up 2% to $566.3 million.
CooperSurgical (CSI) revenue up 35% to $277.1 million.
Non-GAAP diluted earnings per share $3.19, down 6% from last year's third quarter.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
The Company updated its fiscal year 2022 financial guidance.
Positive Outlook
- Fiscal 2022 total revenue $3,290 - $3,310 million (organic growth of 10% to 11%)
- CVI revenue $2,236 - $2,247 million (organic growth of 11% to 12%)
- CSI revenue $1,055 - $1,064 million (organic growth of 7% to 8%)
- Fiscal 2022 non-GAAP diluted EPS $12.72 - $12.87
- Fiscal fourth quarter 2022 total revenue $830 - $850 million (organic growth of 9% to 11%)
Challenges Ahead
- CVI revenue $554 - $565 million (organic growth of 8% to 10%)
- CSI revenue $276 - $285 million (organic growth of 10% to 15%)
- Fiscal fourth quarter 2022 non-GAAP diluted EPS $3.05 - $3.20
- Fiscal year 2022 financial guidance does not include the Cook Medical Reproductive Health acquisition announced on February 7, 2022, as the transaction is pending regulatory approval.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...